News

201 Therapeutics wins US$137.5K grant for liver cancer drugs

What's the deal? 201 TherapeuticsDealroom has a profile for this one. Try Dealroom →, a University of Basel spin-off, has received a US$137.5K (≈$180,000) grant from Venture KickDealroom has a profile for this one. Try Dealroom → to advance targeted therapies for liver cancer. The biotech is developing small-molecule drugs designed to act directly on cancer cells.

What's the endgame? The company has identified two proprietary compound series showing potent anticancer activity and high selectivity against non-malignant liver cells. The grant will fund optimization of its lead compounds and preclinical efficacy data in animal models.

Why now? The funding moves the two drug series from patient-derived tumor organoids into mouse-model validation, a step toward selecting a development candidate. 201 Therapeutics builds its research on miniature tumor models grown from patient biopsies, allowing testing on human cancer cells from the earliest stages of drug discovery.

Liver cancer is the third leading cause of cancer-related deaths worldwide, with over 750,000 deaths annually. Despite advances in immunotherapy, demand remains for therapies with distinct mechanisms, especially for patients whose disease progresses after existing treatments.

The grant extends an early development path. 201 Therapeutics previously received a US$36.7K Venture Kick award in May, followed by a University of Basel grant supporting proof-of-concept work.

The team is led by chief executive officer and co-founder Sandro Nuciforo, with chief technology officer Fredrik Trulsson, chief medical officer Markus Heim, and head of chemistry Emmanuel Meyer.

"Venture Kick challenged us to think beyond the science," said Nuciforo. The program, he added, helped the team "identify the key milestones needed to attract investors and pharmaceutical partners."

The signal: This is an early preclinical milestone, not a major investor commitment, and the grant is modest against the cost and risk of drug development. Its significance will hinge on whether the forthcoming in-vivo studies confirm the organoid results.

Read more: venturekick.ch

Image credit: History at NIH

More top stories